Literature DB >> 20425233

Therapeutic strategies for diabetic neuropathy.

Ali A Habib1, Thomas H Brannagan.   

Abstract

Diabetes is the leading cause of peripheral neuropathy globally. Duration of diabetes, glycemic control, and preexisting cardiovascular risk factors independently correlate with the development and progression of diabetic peripheral neuropathy as well as cardiovascular autonomic neuropathy. The pathogenesis of diabetic neuropathy remains unclear, although insulin resistance, oxidative stress, mitochondrial dysfunction, abnormal glucose metabolism, advanced glycation end products, neurotrophic factors, and protein kinase C activation all may play a role. Strict glycemic control remains the only available treatment option, although other treatments are in development. Multiple options are available for symptom management. In this article, we review factors associated with development and progression of diabetic neuropathy and discuss available treatment options.

Entities:  

Mesh:

Year:  2010        PMID: 20425233     DOI: 10.1007/s11910-010-0093-7

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  49 in total

1.  Cigarette smoking and neuropathy in diabetic patients.

Authors:  B D Mitchell; V M Hawthorne; A I Vinik
Journal:  Diabetes Care       Date:  1990-04       Impact factor: 19.112

2.  A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

Authors:  J F Wernicke; Y L Pritchett; D N D'Souza; A Waninger; P Tran; S Iyengar; J Raskin
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

3.  Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion.

Authors:  Catherine L Martin; James Albers; William H Herman; Patricia Cleary; Barbara Waberski; Douglas A Greene; Martin J Stevens; Eva L Feldman
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

4.  Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia.

Authors:  D Simovic; J M Isner; A H Ropper; A Pieczek; D H Weinberg
Journal:  Arch Neurol       Date:  2001-05

Review 5.  Epidermal nerve fiber quantification in the assessment of diabetic neuropathy.

Authors:  Kristina K Beiswenger; Nigel A Calcutt; Andrew P Mizisin
Journal:  Acta Histochem       Date:  2008-04-01       Impact factor: 2.479

6.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

Review 7.  Advances in the management of diabetic peripheral neuropathy.

Authors:  Solomon Tesfaye
Journal:  Curr Opin Support Palliat Care       Date:  2009-06       Impact factor: 2.302

Review 8.  Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study.

Authors:  Peter J Dyck; P James B Dyck; Christopher J Klein; Stephen D Weigand
Journal:  Muscle Nerve       Date:  2007-10       Impact factor: 3.217

9.  Ranirestat for the management of diabetic sensorimotor polyneuropathy.

Authors:  Vera Bril; Toshiyuki Hirose; Sasagu Tomioka; Robert Buchanan
Journal:  Diabetes Care       Date:  2009-04-14       Impact factor: 19.112

10.  Elevated triglycerides correlate with progression of diabetic neuropathy.

Authors:  Timothy D Wiggin; Kelli A Sullivan; Rodica Pop-Busui; Antonino Amato; Anders A F Sima; Eva L Feldman
Journal:  Diabetes       Date:  2009-05-01       Impact factor: 9.461

View more
  20 in total

1.  In vivo peripheral nervous system insulin signaling.

Authors:  Caleb W Grote; Janelle M Ryals; Douglas E Wright
Journal:  J Peripher Nerv Syst       Date:  2013-09       Impact factor: 3.494

Review 2.  Insulin resistance in the nervous system.

Authors:  Bhumsoo Kim; Eva L Feldman
Journal:  Trends Endocrinol Metab       Date:  2012-01-13       Impact factor: 12.015

3.  Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population.

Authors:  Pravinkumar R Patil; Jonathan Wolfe; Qayyim Said; Jeremy Thomas; Bradley C Martin
Journal:  Clin J Pain       Date:  2015-05       Impact factor: 3.442

4.  Analysis of sphingolipid composition in human vitreous from control and diabetic individuals.

Authors:  Lynda A Wilmott; Richard C Grambergs; Jeremy C Allegood; Timothy J Lyons; Nawajes Mandal
Journal:  J Diabetes Complications       Date:  2018-12-14       Impact factor: 2.852

Review 5.  Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.

Authors:  Hyongbum Kim; Julie J Kim; Young-sup Yoon
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2012-06       Impact factor: 2.895

Review 6.  Enhanced glucose control for preventing and treating diabetic neuropathy.

Authors:  Brian C Callaghan; Ann A Little; Eva L Feldman; Richard A C Hughes
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

7.  Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy.

Authors:  Houliang Deng; JinJin Yin; JingJing Zhang; Qian Xu; Xiaoxia Liu; Li Liu; Zhuomin Wu; Aimin Ji
Journal:  Endocrine       Date:  2014-02-13       Impact factor: 3.633

8.  Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice.

Authors:  Meng Suo; Ping Wang; Mengyuan Zhang
Journal:  J Neurophysiol       Date:  2016-05-04       Impact factor: 2.714

9.  Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model.

Authors:  Tie-Jun Sten Shi; Ming-Dong Zhang; Hugo Zeberg; Johanna Nilsson; Jacob Grünler; Su-Xing Liu; Qiong Xiang; Jonas Persson; Kaj J Fried; Sergiu Bogdan Catrina; Masahiko Watanabe; Peter Arhem; Kerstin Brismar; Tomas G M Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

10.  Centella asiatica triterpenes for diabetic neuropathy: a randomized, double-blind, placebo-controlled, pilot clinical study.

Authors:  Jau-Shin Lou; Diana M Dimitrova; Charles Murchison; Grace C Arnold; Heather Belding; Nick Seifer; Ngoc Le; Sarah B Andrea; Nora E Gray; Kirsten M Wright; Maya Caruso; Amala Soumyanath
Journal:  Esper Dermatol       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.